Hostname: page-component-78c5997874-j824f Total loading time: 0 Render date: 2024-11-19T07:20:15.712Z Has data issue: false hasContentIssue false
  • English
  • Français

Occurrence of nutritional hypocalcaemic rickets-related dilated cardiomyopathy in a child with concomitant rickets and infantile-onset Pompe disease

Part of: Metabolic

Published online by Cambridge University Press:  25 January 2019

Osman Yeşilbaş Open the ORCID record for Osman Yeşilbaş [Opens in a new window]  and
Serdar Epçaçan Open the ORCID record for Serdar Epçaçan [Opens in a new window]
Osman Yeşilbaş*
Affiliation:
Pediatric Intensive Care Unit, Van Training and Research Hospital, University of Health Sciences, Van, Turkey
Serdar Epçaçan
Affiliation:
Pediatric Cardiology, Van Training and Research Hospital, University of Health Sciences, Van, Turkey
*
Author for correspondence: O. Yesilbas, MD, Pediatric Intensive Care Unit, Van Training and Research Hospital, University of Health Sciences, Süphan Mahallesi, Havayolu Kavşağı, Edremit, Van 65300, Turkey. Tel: +90 533 541 97 22; Fax: +90 432 212 19 54; E-mail: [email protected]
Get access Rights & Permissions [Opens in a new window]

Abstract

Infantile-onset Pompe disease is a lysosomal storage disorder characterised with hypertrophic cardiomyopathy, respiratory insufficiency, and hypotonia. Dilated cardiomyopathy is an extremely rare and curable complication of nutritional hypocalcaemic rickets. A 3-month-old female infant was referred to our paediatric ICU with a 4-day history of fatigue, tachypnoea, tachycardia, hypoxia, and respiratory failure. According to the laboratory, radiology, and echocardiography findings, she was first diagnosed with nutritional hypocalcaemic rickets-related dilated cardiomyopathy, but vitamin D and elementary calcium supplementation unmasked the underlying infantile-onset Pompe disease. Nutritional hypocalcaemic rickets and infantile-onset Pompe disease must always be kept in mind among the causes of concomitant dilated cardiomyopathy and hypertrophic cardiomyopathy.

Keywords

Dilated cardiomyopathyhypertrophic cardiomyopathyinfantile-onset Pompe diseasenutritional hypocalcaemic rickets
Type
Brief Report
Information
Cardiology in the Young , Volume 29 , Issue 3 , March 2019 , pp. 425 - 427
Copyright
© Cambridge University Press 2019 

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

Footnotes

Cite this article: Yeşilbaş O, Epçaçan S. (2019) Occurrence of nutritional hypocalcaemic rickets-related dilated cardiomyopathy in a child with concomitant rickets and infantile-onset Pompe disease. Cardiology in the Young29: 425–427. doi: 10.1017/S1047951118002287

References

1. Owens, P, Wong, M, Bhattacharya, K, Ellaway, C. Infantile-onset Pompe disease: a case series highlighting early clinical features, spectrum of disease severity and treatment response. J Paediatr Child Health 2018; 54: 1255–1261.Google Scholar
2. Löscher, WN, Huemer, M, Stulnig, TM, et al. Pompe disease in Austria: clinical, genetic and epidemiological aspects. J Neurol 2018; 265: 159–164.Google Scholar
3. Brown, J, Nunez, S, Russell, M, Spurney, C. Hypocalcemic rickets and dilated cardiomyopathy: case reports and review of literature. Pediatr Cardiol 2009; 30: 818–823.Google Scholar
4. Verma, S, Khadwal, A, Chopra, K, Rohit, M, Singhi, S. Hypocalcemia nutritional rickets: a curable cause of dilated cardiomyopathy. J Trop Pediatr 2011; 57: 126–128.Google Scholar
5. Yilmaz, O, Olgun, H, Ciftel, M, et al. Dilated cardiomyopathy secondary to rickets-related hypocalcaemia: eight case reports and a review of the literature. Cardiol Young 2015; 25: 261–266.Google Scholar
6. Olgun, H, Ceviz, N, Ozkan, B. A case of dilated cardiomyopathy due to nutritional vitamin D deficiency rickets. Turk J Pediatr 2003; 45: 152–154.Google Scholar
7. Al-Hassnan, ZN, Khalifa, OA, Bubshait, DK, et al. The phenotype, genotype, and outcome of infantile-onset Pompe disease in 18 Saudi patients. Mol Genet Metab Rep 2018; 15: 50–54.Google Scholar
8. Felice, T. Pompe disease, a storage cardiomyopathy. Cardiogenetics 2017; 7: 22–27.Google Scholar
9. Nicolino, M, Byrne, B, Wraith, JE, et al. Clinical outcomes after long-term treatment with alglucosidase alfa in infants and children with advanced Pompe disease. Genet Med 2009; 11: 210–219.Google Scholar
10. Kishnani, PS, Corzo, D, Nicolino, M, et al. Recombinant human acid α-glucosidase: Major clinical benefits in infantile-onset Pompe disease. Neurology 2007; 68: 99–109.10.1212/01.wnl.0000251268.41188.04Google Scholar
11. Kishnani, PS, Corzo, D, Leslie, ND, et al. Early treatment with alglucosidase alpha prolongs long-term survival of infants with Pompe disease. Pediatr Res 2009; 66: 329–335.Google Scholar